Glecaprevir/pibrentasvir in patients aged 3–17 years with chronic hepatitis C: Real‐life data from the POLAC project
Journal of Pediatric Gastroenterology and Nutrition · 2026
DOI: 10.1002/jpn3.70241 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pediatric Gastroenterology and Nutrition, 2026. Verfasst von Anna Dobrzeniecka und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Children's Infectious Diseases, Medical University of Warsaw, Warsaw, Poland. Hauptthemen laut MEDLINE: Hepatitis C, Chronic, Quinoxalines, Benzimidazoles, Sulfonamides. Die Arbeit nennt 29 Literaturangaben. Gefördert von: None.
Abstract (Originalsprache)
Objectives
In this noncommercial, nonrandomized, open‐label therapeutic program POLAC project, we aimed to analyze the efficacy and safety of the pangenotypic regimen glecaprevir/pibrentasvir (GLE/PIB) in children aged 3–17 years with chronic hepatitis C.
Methods
Eligible patients for 8‐week therapy with GLE/PIB were divided into two age groups. Patients above 12 years of age received tablets containing a fixed dose of 300/120 mg GLE/PIB, and patients below 12 years weighing 12–45 kg were treated with granule formula adjusted to patients' weight. The primary endpoint of the study was treatment efficacy, defined as sustained virologic response at 12 weeks posttreatment (SVR12, undetectable hepatitis C virus (HCV) RNA using a real‐time polymerase chain reaction).
Results
We included 63 patients, 21 received tablets, and 42 received the granules formula. Median age of the patients was 8 years (interquartile range, IQR 6–12). There were 37 (59%) males. Fifty‐nine children (94%) were infected vertically. Most patients (43, 68%) had genotype 1 HCV. Four patients presented with significant fibrosis (F2‐F3 METAVIR) at baseline, but there were no cases of cirrhosis. Sixty‐two patients (98%) achieved SVR12. One patient was lost to follow‐up before SVR12 evaluation; however, at the end of therapy, his HCV RNA levels were undetectable. Thirty‐two patients (51%) had adverse events (AEs). There were 49 AEs possibly related to the treatment, all mild. The most frequent AEs included abdominal pain (14%), fatigue (11%), and pruritus (11%).
Conclusions
Our study confirms that 8 weeks of therapy with GLE/PIB in children with chronic hepatitis C is highly effective and safe.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Children's Infectious Diseases, Medical University of Warsaw, Warsaw, Poland.
- Department of Pediatric Infectious Diseases, Regional Hospital of Infectious Diseases in Warsaw, Warsaw, Poland.
ORCID-Profile: Anna Dobrzeniecka
Förderung
- None
Zitieren
APA
Dobrzeniecka, A., Talarek, E., Aniszewska, M., Troszczyńska, M., Marczyńska, M., & Pokorska-Śpiewak, M. (2026). Glecaprevir/pibrentasvir in patients aged 3–17 years with chronic hepatitis C: Real‐life data from the POLAC project. Journal of Pediatric Gastroenterology and Nutrition. https://doi.org/10.1002/jpn3.70241
Vancouver
Dobrzeniecka A, Talarek E, Aniszewska M, Troszczyńska M, Marczyńska M, Pokorska-Śpiewak M. Glecaprevir/pibrentasvir in patients aged 3–17 years with chronic hepatitis C: Real‐life data from the POLAC project. Journal of Pediatric Gastroenterology and Nutrition. 2026. doi:10.1002/jpn3.70241
BibTeX
@article{Dobrzeniecka2026,
author = {Dobrzeniecka, Anna and Talarek, Ewa and Aniszewska, Małgorzata and Troszczyńska, Marta and Marczyńska, Magdalena and Pokorska-Śpiewak, Maria},
title = {Glecaprevir/pibrentasvir in patients aged 3–17 years with chronic hepatitis C: Real‐life data from the POLAC project},
journal = {Journal of Pediatric Gastroenterology and Nutrition},
year = {2026},
doi = {10.1002/jpn3.70241}
}
EUVIMED